【摘要】：正伏立康唑?yàn)閺V譜抗真菌藥物,主要經(jīng)肝藥代謝酶CYP2C19、或CYP3A4和CYP2C9代謝,其藥動(dòng)學(xué)特征呈非線(xiàn)性并變異程度大,且該藥治療窗窄,使臨床應(yīng)用復(fù)雜。本研究將4項(xiàng)健康受試者研究和2項(xiàng)患者臨床研究的數(shù)據(jù)(包括240名受試者的3 352個(gè)血藥濃度數(shù)據(jù))建立非線(xiàn)性混合效應(yīng)模型分析(NONMEM),以劑量模擬檢驗(yàn)協(xié)變量影響效應(yīng)和據(jù)CYP2C19表型分層的伏立康唑濃度(2~5 mg/L)達(dá)
[Abstract]:N-voliconazole is a broad-spectrum antifungal drug, which is mainly metabolized by liver drug metabolizing enzymes CYP2C19, or CYP3A4 and CYP2C9. Its pharmacokinetics is nonlinear and varied greatly, and the therapeutic window of the drug is narrow, which makes the clinical application complex. In this study, a nonlinear mixed effect model was established based on the data of 4 healthy subjects and 2 clinical studies (including 3,352 blood concentration data of 240 subjects). (NONMEM), was analyzed by dose simulation to test the covariable effect and the concentration of voliconazole layered according to CYP2C19 phenotype (2 鈮，

本文編號(hào)：2520106